Race Oncology has announced that Dr Daniel Tillett has been appointed full-time Chief Executive Officer. 

Dr Tillett’s appointment is effective immediately and he will work alongside Executive Director, Dr Pete Smith, to advance Race’s strategic, clinical and commercialisation plans for bisantrene. 

Through this arrangement, Dr Pete Smith will focus on partnering, business development and institutional outreach strategy, while Dr Daniel Tillett will have carriage of clinical strategy, implementation and shareholder engagement. 

You can read more about the appointment here.

Updated Strategic Plan

Race has also released an updated strategic plan that is focused on continuing the clinical development strategy within Australia to achieve commercial goals using available resources.

The new clinical program is designed to establish anthracycline cardioprotection and clinical effects on the m6A RNA pathway using Race’s bisantrene RC220 in a range of solid tumours. 

The Phase 1a/b trial is fully funded and Race has released a Bonus Option to reward loyal shareholders and fund Phase 2 efficacy studies in both solid tumours and AML. 

For more details on the new strategy, please read the announcement and investor presentation here. 

In addition, shareholders can access the Bonus Option Prospectus here.